We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Targeted therapy and immunotherapy for T cell acute lymphoblastic leukemia/lymphoma.
- Authors
Huang, Yuan-hong; Wan, Chao-Ling; Dai, Hai-ping; Xue, Sheng-li
- Abstract
T cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive malignancy of progenitor T cells. Despite significant improvements in survival of T-ALL/LBL over the past decades, treatment of relapsed and refractory T-ALL (R/R T-ALL/LBL) remains extremely challenging. The prognosis of R/R T-ALL/LBL patients who are intolerant to intensive chemotherapy remains poor. Therefore, innovative approaches are needed to further improve the survival of R/R T-ALL/LBL patients. With the widespread use of next-generation sequencing in T-ALL/LBL, a range of new therapeutic targets such as NOTCH1 inhibitors, JAK-STAT inhibitors, and tyrosine kinase inhibitors have been identified. These findings led to pre-clinical studies and clinical trials of molecular targeted therapy in T-ALL/LBL. Furthermore, immunotherapies such as CD7 CAR T cell therapy and CD5 CAR T cell therapy have shown profound response rate in R/R T-ALL/LBL. Here, we review the progress of targeted therapies and immunotherapies for T-ALL/LBL, and look at the future directions and challenges for the further use of these therapies in T-ALL/LBL.
- Subjects
LYMPHOBLASTIC leukemia; CHIMERIC antigen receptors; T cells; ACUTE leukemia; LYMPHOMAS
- Publication
Annals of Hematology, 2023, Vol 102, Issue 8, p2001
- ISSN
0939-5555
- Publication type
Article
- DOI
10.1007/s00277-023-05286-3